Chemotherapy after first-line EGFR TKI fails to extend survival in advanced NSCLC
CHICAGO — Platinum-doublet chemotherapy did not extend survival for patients with advanced nonsquamous non-small cell lung cancer who responded to EGFR tyrosine kinase inhibitor therapy, according to randomized phase 3 study results.The regimen prolonged PFS but did not confer an OS benefit, findings presented at ASCO Annual Meeting showed.
Source: healio.com